Home » WHO PQP Will Pilot Prequalification of Selected APIs
WHO PQP Will Pilot Prequalification of Selected APIs
The WHO Prequalification of Medicines Programme (PQP) will pilot prequalification of selected active pharmaceutical ingredients (APIs) for products for treating HIV and related diseases, for antimalarial medicinal products and for anti-tuberculosis products, as of 21 October 2010.
Globalization of pharmaceutical production has led to diversification of API sources and made verification of API quality more difficult. WHO's decision to start prequalification of APIs responds to concern increasingly expressed by medicines regulators regarding API quality, especially with respect to non-compliance with Good Manufacturing Practices (GMP).
WHO PQP already assesses API master files (APIMFs) as part of its evaluation of finished pharmaceutical products (FPPs). This can include inspection of the manufacturing site(s) to assess compliance with WHO GMP, if risk assessment indicates that on-site inspection is necessary. An API submitted for evaluation will generally undergo both dossier assessment and inspection of the manufacturing site.
Each prequalified API — including details of the supplier and manufacturing site(s) — will be added to the WHO List of Prequalified Active Pharmaceutical Ingredients. The List will be of great interest to FPP manufacturers seeking to ensure the good quality of APIs used in their FPP production, and to national medicines regulatory authorities who wish to verify the standard of APIs that have been used to manufacture nationally registered medicines or medicines for which an application for registration has been received.
It is expected that time taken to reach prequalification will be shorter for FPPs that are manufactured using WHO-prequalified APIs, than for FPPs that are manufactured using APIs that have not previously been evaluated by WHO PQP.
An APIMF that has already been accepted by WHO in relation to the prequalification of an FPP may be included in the WHO List of Prequalified APIs without reassessment or re-inspection. This is contingent upon the APIMF meeting certain administrative criteria and the relevant manufacturing site(s) having passed inspection by WHO or a stringent regulatory authority.
Selection of APIs for inclusion in the 1st Invitation was based on APIs for which APIMFs have already been submitted in connection with evaluation of an FPP. WHO PQP anticipates that future Invitations will be expanded to incorporate additional APIs. New Invitations will be posted on the PQP web site and manufacturers are therefore encouraged to consult it regularly.
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »